when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Rybelsus · news · pharmadog

← back to Rybelsus

News mentioning Rybelsus

54 stories

2dKailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOSbiospace

3dFresenius Kabi manufacturing plant hit with FDA warning letter after adverse eventsbiospace

4dSanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&Dfiercebiotech

4dSuperior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3biospace

4dLilly builds commercial case for GLP-1 products over Novo with indirect analysesbiospace

4dLilly raises diabetes weight-loss bar with amylin-Zepbound combofiercebiotech

5dNovo adds long-term obesity differentiation in up to $2.6B Hengrui dealbiospace

7dRoche drops muscle-sparing obesity antibody after flunked interim analysisfiercebiotech

10dFDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’biospace

12dNovo’s workforce reduction climbs to 13,000 to fuel R&D workbiospace

13dNovo talks up drug launches in effort to win back investorsbiopharma dive

13dNovo’s plan to hit $23B in revenue by 2035 leaves investors wantingbiospace

13dNovo buys three early-stage obesity assets from Kallyope as investor pressure mountsbiospace

14dNovo struggles to appease restive investors with consumer plans, blockbuster ambitionsfiercebiotech

14dAre healthcare systems really ready for GLP-1s?biopharma dive

16dArtelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese micefiercebiotech

17dRefreshed Novo corrals 3 new early-stage obesity drugs from Kallyopefiercebiotech

18d'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrandfiercebiotech

20dNovo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendisfiercebiotech

21dNo more Nordisk as Novo goes it alone amid rebranding pushfiercebiotech

25dWebinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Marketsbiospace

26dTelemedicine company offers GLP-1s for addictionstat

Sep 4, 26Menarini signs $771M deal to take Gan & Lee GLP-1 to European marketfiercebiotech

Aug 28, 26Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjarobiospace

Aug 27, 26Myriad catalysts on deck for obesity’s brightest stars as market continues to acceleratebiospace

Aug 21, 26Novo Nordisk starts trialing lower maintenance doses of oral Wegovybiospace

Aug 19, 26Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?biospace

Aug 18, 26Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemiabiospace

Aug 17, 26Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 winfiercebiotech

Aug 14, 26Skye and Redx form new entity with $125M to advance fibrosis assetsfiercebiotech

← prevpage 1 of 2next →